镭-223治疗转移性去势抵抗性前列腺癌患者的健康相关生活质量、心理困扰与疲劳
这项多中心前瞻性观察队列研究纳入122例接受镭-223治疗的转移性去势抵抗性前列腺癌患者,主要终点为EORTC QLQ-C30和BM-22测量的健康相关生活质量。完成治疗者生活质量稳定、心理困扰和疲劳保持稳定,中断治疗者基线更差且随时间有意义恶化;基线使用阿片类药物、低血红蛋白和高碱性磷酸酶者生活质量恶化可能性更高。
要点
- 完成镭-223治疗者健康相关生活质量稳定,心理困扰和疲劳保持稳定。
- 中断治疗者基线和随访期间的健康相关生活质量、心理困扰和疲劳均更差。
- 基线使用阿片类药物、低血红蛋白和高碱性磷酸酶者生活质量恶化可能性更高。
核心结论
- 中断镭-223治疗的患者相比完成治疗者基线健康相关生活质量、心理困扰和疲劳更差,且随访期间更频繁出现恶化。
- 对镭-223治疗前使用阿片类药物、低血红蛋白和高碱性磷酸酶的患者,随访中需特别关注健康相关生活质量。
研究设计与样本
- 多中心前瞻性观察队列研究,共纳入122例接受镭-223治疗的转移性去势抵抗性前列腺癌患者进行分析。
- 主要终点为EORTC QLQ-C30和BM-22问卷测量的癌症特异性及骨转移相关健康相关生活质量。
- 次要终点为HADS和CIS-Fatigue问卷评估的心理困扰和疲劳。
- 按镭-223注射次数分为1-3次、4-5次和6次亚组进行分析,并进行轨迹分析探索健康相关生活质量随时间的变化模式。
主要发现
- 完成镭-223治疗的患者健康相关生活质量稳定,心理困扰和疲劳保持稳定。
- 中断镭-223治疗的患者随时间出现临床意义且统计学显著的健康相关生活质量、心理困扰和疲劳恶化。
- 轨迹分析显示,基线使用阿片类药物、低血红蛋白和高碱性磷酸酶水平的患者健康相关生活质量随时间恶化的可能性更高。
- 未完成镭-223治疗的患者基线健康相关生活质量、疼痛强度、心理困扰和疲劳更差。
关键数值与推荐
- 主要终点采用EORTC QLQ-C30和BM-22问卷测量癌症特异性及骨转移相关健康相关生活质量。
- 次要终点采用HADS评估心理困扰、CIS-Fatigue评估疲劳。
- 亚组分析按镭-223注射次数分为1-3次、4-5次和6次。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radium-223 is a registered treatment option for symptomatic bone metastatic castration-resistant prostate cancer (mCRPC). Aim of this multicenter, prospective observational cohort study was to evaluate health-related quality of life (HR-QoL), psychological distress and fatigue in mCRPC patients treated with radium-223. METHODS: Primary endpoint was cancer-specific and bone metastases-related HR-QoL, as measured by the EORTC QLQ-C30 and BM-22 questionnaires. Secondary endpoints were psychological distress and fatigue, evaluated by the HADS and CIS-Fatigue questionnaires. Outcomes were analyzed for the total cohort and between subgroups (1-3 versus 4-5 versus 6 radium-223 injections). A trajectory analysis was performed to explore HR-QoL patterns over time. RESULTS: In total, 122 patients were included for analysis. Baseline HR-QoL, pain intensity, psychological distress and fatigue were worse in patients who did not complete radium-223 therapy. In patients who completed therapy, stabilization of HR-QoL was perceived and psychological distress and fatigue remained stable, whereas clinically meaningful and statistically significant deterioration of HR-QoL, psychological distress and fatigue over time was observed in patients who discontinued radium-223 therapy. Trajectory analysis revealed that HR-QoL deterioration over time was more likely in patients with baseline opioid use, low hemoglobin and high alkaline phosphatase levels. CONCLUSIONS: Patients who discontinued radium-223 therapy showed worse HR-QoL, psychological distress and fatigue at baseline and more frequent deterioration of HR-QoL, psychological distress and fatigue over time when compared to patients who completed therapy. Specific attention with regard to HR-QoL during follow-up is indicated in patients with opioid use, low hemoglobin and high alkaline phosphatase levels before radium-223 therapy initiation. CLINICAL TRIAL REGISTRATION NUMBER: NCT04995614.
引用
- van der Doelen MJ, Oving IM, Wyndaele DNJ, et al. Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy. Prostate Cancer Prostatic Dis. 2022. PMID: 35804188. doi:10.1038/s41391-022-00569-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。